BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 33221969)

  • 21. Early Assessment of Response to Neoadjuvant Chemotherapy with 18F-FDG-PET/CT in Patients with Advanced-Stage Ovarian Cancer.
    Chung YS; Kim HS; Lee JY; Kang WJ; Nam EJ; Kim S; Kim SW; Kim YT
    Cancer Res Treat; 2020 Oct; 52(4):1211-1218. PubMed ID: 32599990
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of EORTC criteria and PERCIST for PET/CT response evaluation of patients with metastatic colorectal cancer treated with irinotecan and cetuximab.
    Skougaard K; Nielsen D; Jensen BV; Hendel HW
    J Nucl Med; 2013 Jul; 54(7):1026-31. PubMed ID: 23572497
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Volume-based quantitative FDG PET/CT metrics and their association with optimal debulking and progression-free survival in patients with recurrent ovarian cancer undergoing secondary cytoreductive surgery.
    Vargas HA; Burger IA; Goldman DA; Miccò M; Sosa RE; Weber W; Chi DS; Hricak H; Sala E
    Eur Radiol; 2015 Nov; 25(11):3348-53. PubMed ID: 25916387
    [TBL] [Abstract][Full Text] [Related]  

  • 24. 18F-FDG PET/CT During Neoadjuvant Targeted Therapy in Prior Unresectable Stage III Melanoma Patients: Can (Early) Metabolic Imaging Predict Histopathologic Response or Recurrence?
    van der Hiel B; Blankenstein SA; Aalbersberg EA; Wondergem M; Stokkel MPM; van de Wiel BA; Klop WMC; van Akkooi ACJ; Haanen JB
    Clin Nucl Med; 2022 Jul; 47(7):583-589. PubMed ID: 35452004
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The early prediction of pathological response to neoadjuvant chemotherapy and prognosis: comparison of PET Response Criteria in Solid Tumors and European Organization for Research and Treatment of Cancer criteria in breast cancer.
    Lian W; Liu C; Gu B; Zhang J; Lu L; Pan H; Yao Z; Wang M; Song S; Zhang Y; Yang Z
    Nucl Med Commun; 2020 Mar; 41(3):280-287. PubMed ID: 32032193
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The role of metabolic tumor volume and total lesion glycolysis on ¹⁸F-FDG PET/CT in the prognosis of epithelial ovarian cancer.
    Lee JW; Cho A; Lee JH; Yun M; Lee JD; Kim YT; Kang WJ
    Eur J Nucl Med Mol Imaging; 2014 Oct; 41(10):1898-906. PubMed ID: 24852188
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [
    Annovazzi A; Ferraresi V; Anelli V; Covello R; Vari S; Zoccali C; Biagini R; Sciuto R
    Eur Radiol; 2021 Sep; 31(9):7012-7021. PubMed ID: 33715090
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Diffuse Large B-Cell Lymphoma: Prospective Multicenter Comparison of Early Interim FLT PET/CT versus FDG PET/CT with IHP, EORTC, Deauville, and PERCIST Criteria for Early Therapeutic Monitoring.
    Minamimoto R; Fayad L; Advani R; Vose J; Macapinlac H; Meza J; Hankins J; Mottaghy F; Juweid M; Quon A
    Radiology; 2016 Jul; 280(1):220-9. PubMed ID: 26854705
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The efficiency of
    Tao X; Li N; Wu N; He J; Ying J; Gao S; Wang S; Wang J; Wang Z; Ling Y; Tang W; Zhang Z
    Eur J Nucl Med Mol Imaging; 2020 May; 47(5):1209-1219. PubMed ID: 32043180
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prognostic and predictive role of [
    Zucali PA; Lopci E; Ceresoli GL; Giordano L; Perrino M; Ciocia G; Gianoncelli L; Lorenzi E; Simonelli M; De Vincenzo F; Setti LR; Bonifacio C; Bonomi M; Bombardieri E; Chiti A; Santoro A
    Cancer Med; 2017 Oct; 6(10):2287-2296. PubMed ID: 28941158
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Usefulness of
    Yokose T; Kitago M; Matsusaka Y; Masugi Y; Shinoda M; Yagi H; Abe Y; Oshima G; Hori S; Endo Y; Toyama K; Iwabuchi Y; Takemura R; Ishii R; Nakahara T; Okuda S; Jinzaki M; Kitagawa Y
    Cancer Med; 2020 Jun; 9(12):4059-4068. PubMed ID: 32281301
    [TBL] [Abstract][Full Text] [Related]  

  • 32. 18F-FDG PET/CT of Non-Small Cell Lung Carcinoma Under Neoadjuvant Chemotherapy: Background-Based Adaptive-Volume Metrics Outperform TLG and MTV in Predicting Histopathologic Response.
    Burger IA; Casanova R; Steiger S; Husmann L; Stolzmann P; Huellner MW; Curioni A; Hillinger S; Schmidtlein CR; Soltermann A
    J Nucl Med; 2016 Jun; 57(6):849-54. PubMed ID: 26823566
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical Value of
    Hynninen J; Laasik M; Vallius T; Kemppainen J; Grönroos S; Virtanen J; Casado J; Hautaniemi S; Grenman S; Seppänen M; Auranen A
    Clin Oncol (R Coll Radiol); 2018 Aug; 30(8):507-514. PubMed ID: 29753662
    [TBL] [Abstract][Full Text] [Related]  

  • 34. 3'-Deoxy-3'-
    Kim JE; Chae SY; Kim JH; Kim HJ; Kim TW; Kim KP; Kim SY; Lee JL; Oh SJ; Kim JS; Ryu JS; Moon DH; Hong YS
    Eur J Nucl Med Mol Imaging; 2019 Jul; 46(8):1713-1722. PubMed ID: 31041456
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Baseline and interim [18F]FDG-PET/MRI to assess treatment response and survival in patients with M0 esophageal squamous cell carcinoma treated by curative-intent therapy.
    Chao YK; Chang CB; Chang YC; Chan SC; Chiu CH; Ng SH; Hsieh JC; Wang JH
    Cancer Imaging; 2023 Nov; 23(1):109. PubMed ID: 37932848
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparative analysis of different response criteria at early phase after PD-1 blockade in non-small lung cancer.
    Kaira K; Yamaguchi O; Naruse I; Umeda Y; Honda T; Watanabe S; Ichikawa K; Yanagisawa S; Kasahara N; Higuchi T; Hashimoto K; Miura Y; Shiono A; Mouri A; Imai H; Iizuka K; Ishizuka T; Minato K; Suda S; Kagamu H; Mori K; Seki N; Kuji I
    Cancer Imaging; 2023 Mar; 23(1):23. PubMed ID: 36859341
    [TBL] [Abstract][Full Text] [Related]  

  • 37. 18F-FDG-PET/CT can identify histopathological non-responders to platinum-based neoadjuvant chemotherapy in advanced epithelial ovarian cancer.
    Vallius T; Peter A; Auranen A; Carpén O; Kemppainen J; Matomäki J; Oksa S; Roering P; Seppänen M; Grénman S; Hynninen J
    Gynecol Oncol; 2016 Jan; 140(1):29-35. PubMed ID: 26515076
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Intra-tumor metabolic heterogeneity of gastric cancer on
    Liu G; Yin H; Cheng X; Wang Y; Hu Y; Liu T; Shi H
    Clin Exp Med; 2021 Feb; 21(1):129-138. PubMed ID: 32880779
    [TBL] [Abstract][Full Text] [Related]  

  • 39.
    Fledelius J; Winther-Larsen A; Khalil AA; Bylov CM; Hjorthaug K; Bertelsen A; Frøkiær J; Meldgaard P
    J Nucl Med; 2017 Dec; 58(12):1931-1937. PubMed ID: 28490472
    [TBL] [Abstract][Full Text] [Related]  

  • 40. What
    Turgeon GA; Iravani A; Akhurst T; Beaulieu A; Callahan JW; Bressel M; Cole AJ; Everitt SJ; Siva S; Hicks RJ; Ball DL; Mac Manus MP
    J Nucl Med; 2019 Mar; 60(3):328-334. PubMed ID: 30030343
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.